Sugi Predict

Sugi Predict / Compounds / SCHEMBL671376

SCHEMBL671376

SCHEMBL671376

CCOC(=O)c1cccc(S)c1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 2/20 0.59
▸ ALDH1A1 P00352 2/20 0.51
▸ HSD17B10 Q99714 1/20 0.51
▸ TDP1 Q9NUW8 2/20 0.50
▸ TP53 P04637 1/20 0.50
▸ HTT P42858 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ CDC25B P30305 3/20 0.48
▸ CA12 O43570 3/20 0.47
▸ CA1 P00915 3/20 0.47
▸ CA2 P00918 3/20 0.47
▸ CA7 P43166 3/20 0.47
▸ CA9 Q16790 3/20 0.47
▸ CA14 Q9ULX7 3/20 0.47
▸ MRGPRX4 Q96LA9 1/20 0.47
▸ CYP1A2 P05177 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7467330 0.88 TSHR (0.70) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL830006 0.83 TSHR (0.63) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL14992393 0.83 TSHR (0.63) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL30305694 0.82 TSHR (0.74) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL945371 0.82 TSHR (0.74) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL7728983 0.81 CA12 (0.62) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL22702311 0.81 TSHR (0.61) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL1401561 0.81 TSHR (0.61) TSHRALDH1A1HSD17B10TDP1TP53
SCHEMBL31650794 0.81 TSHR (0.61) TSHRALDH1A1HSD17B10CDC25BCA12
SCHEMBL31650800 0.81 TSHR (0.61) TSHRALDH1A1HSD17B10CDC25BCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116239577-A Method for preparing cudexestat 沈阳药科大学 2023-06-09 — — CN claimed
US-12458627-B2 Autotaxin inhibitors and uses thereof DF 2024 IP ACQUISITION, LLC (US) 2025-11-04 — — US disclosed
US-12268668-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2025-04-08 — — US disclosed
US-20240189281-A1 AUTOTAXIN INHIBITOR COMPOUNDS SABRE THERAPEUTICS LLC (US) 2024-06-13 — — US disclosed
US-11779568-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2023-10-10 — — US disclosed
US-11779568-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2023-10-10 — — US disclosed
US-11779568-B2 Autotaxin inhibitor compounds SABRE THERAPEUTICS LLC (US) 2023-10-10 — — US disclosed
CN-116239577-A Method for preparing cudexestat 沈阳药科大学 2023-06-09 — — CN disclosed
CN-116059203-A Autotaxin inhibitors and uses thereof 赛博治疗有限责任公司 2023-05-05 — — CN disclosed
CN-110372671-B Autotaxin inhibitor compounds 赛博治疗有限责任公司 2023-02-21 — — CN disclosed
US-9000025-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2015-04-07 — — US disclosed
US-9000025-B2 Autotaxin inhibitors and uses thereof AMIRA PHARMACEUTICALS, INC. (US) 2015-04-07 — — US disclosed
WO-2015048301-A1 AUTOTAXIN INHIBITOR COMPOUNDS PHARMAKEA, INC. (US) 2015-04-02 — — WO disclosed
WO-2015048301-A1 AUTOTAXIN INHIBITOR COMPOUNDS PHARMAKEA, INC. (US) 2015-04-02 — — WO disclosed
EP-2606031-A2 AUTOTAXIN INHIBITORS AND USES THEREOF Amira Pharmaceuticals, Inc. (US) 2013-06-26 — — EP disclosed
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2013-06-13 — — US disclosed
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2013-06-13 — — US disclosed
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2013-06-13 — — US disclosed
WO-2012024620-A2 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2012-02-23 — — WO disclosed
WO-2012024620-A2 AUTOTAXIN INHIBITORS AND USES THEREOF AMIRA PHARMACEUTICALS, INC. (US) 2012-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150326-A1 AUTOTAXIN INHIBITORS AND USES THEREOF ENPP2, SERPINB1, SERPINE1 TSHR 2622/4885ALDH1A1 4786/4885HSD17B10 3308/4885
US-11779568-B2 Autotaxin inhibitor compounds ENPP2, SERPINB1, SERPINE1 TSHR 3066/4885ALDH1A1 4720/4885HSD17B10 2873/4885
US-12458627-B2 Autotaxin inhibitors and uses thereof ENPP2, SERPINB1, RNASE1 TSHR 2354/4885ALDH1A1 4716/4885HSD17B10 2721/4885
US-20240189281-A1 AUTOTAXIN INHIBITOR COMPOUNDS ENPP2, SERPINB1, SERPINE1 TSHR 3066/4885ALDH1A1 4720/4885HSD17B10 2873/4885
US-12268668-B2 Autotaxin inhibitor compounds ENPP2, SERPINB1, SERPINE1 TSHR 3066/4885ALDH1A1 4720/4885HSD17B10 2873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.